Clinical update on COVID-19 for the emergency and critical care clinician: Medical management - 14/05/22

Doi : 10.1016/j.ajem.2022.03.036

Brit Long, MD ^a,^{^⁎,}^{^{1
Co primary authors.}} , Summer Chavez, DO, MPH ^b,^{^{1
Co primary authors.}} , Brandon M. Carius, DSc, MPAS, PA-C ^c , William J. Brady, MD ^d , Stephen Y. Liang, MD, MPHS ^e , Alex Koyfman, MD ^f , Michael Gottlieb, MD ^g
^a SAUSHEC, Emergency Medicine, Brooke Army Medical Center, 3551 Roger Brooke Dr, Fort Sam Houston, TX, USA
^b Department of Emergency Medicine, UT Health Houston McGovern School of Medicine, 6431 Fannin Street, Houston, TX, 77030, USA
^c 121 Field Hospital, Camp Humphreys, US Army, Republic of Korea
^d Department of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA
^e Divisions of Emergency Medicine and Infectious Diseases, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO, 63110, USA
^f The University of Texas Southwestern Medical Center, Department of Emergency Medicine, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA
^g Department of Emergency Medicine, Rush University Medical Center, Chicago, IL, USA

^⁎Corresponding author at: 3841 Roger Brooke Dr, Fort Sam Houston, TX 78234, USA.3841 Roger Brooke DrFort Sam HoustonTX78234USA

connettersi o creare un account

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Introduction

Coronavirus disease of 2019 (COVID-19) has resulted in millions of cases worldwide. As the pandemic has progressed, the understanding of this disease has evolved.

Objective

This is the second part in a series on COVID-19 updates providing a focused overview of the medical management of COVID-19 for emergency and critical care clinicians.

Discussion

COVID-19, caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. A variety of medical therapies have been introduced for use, including steroids, antivirals, interleukin-6 antagonists, monoclonal antibodies, and kinase inhibitors. These agents have each demonstrated utility in certain patient subsets. Prophylactic anticoagulation in admitted patients demonstrates improved outcomes. Further randomized data concerning aspirin in outpatients with COVID-19 are needed. Any beneficial impact of other therapies, such as colchicine, convalescent plasma, famotidine, ivermectin, and vitamins and minerals is not present in reliable medical literature. In addition, chloroquine and hydroxychloroquine are not recommended.

Conclusion

This review provides a focused update of the medical management of COVID-19 for emergency and critical care clinicians to help improve care for these patients.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Coronavirus-2019, COVID-19, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2

Mappa

Interleukin-6 antagonists

Monoclonal antibodies

Kinase inhibitors

Antibiotics

Venous thromboembolic (VTE) prophylaxis

Controversial and experimental treatments

Conclusions

Credit authorship contribution statement

Esportazione

Vol 56

P. 158-170 - Giugno 2022 Ritorno al numero

Articolo precedente

High risk and low prevalence diseases: Ovarian torsion
Rachel E. Bridwell, Alex Koyfman, Brit Long

| Articolo seguente

The association between pregnancy and COVID-19: A systematic review and meta-analysis
Hao Wang, Ning Li, Chenyu Sun, Xianwei Guo, Wanying Su, Qiuxia Song, Qiwei Liang, Mingming Liang, Xiuxiu Ding, Scott Lowe, Rachel Bentley, Yehuan Sun

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

connettersi o creare un account

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management - 14/05/22

Abstract

Introduction

Objective

Discussion

Conclusion

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL